Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives $5.67 Consensus Target Price from Brokerages

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has been assigned an average recommendation of “Moderate Buy” from the six analysts that are presently covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $5.67.

Several research firms have recently issued reports on SGMO. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective on shares of Sangamo Therapeutics in a research note on Wednesday, May 15th. Royal Bank of Canada reissued a “sector perform” rating and set a $2.00 price objective on shares of Sangamo Therapeutics in a research report on Thursday, March 14th. Finally, StockNews.com started coverage on shares of Sangamo Therapeutics in a research report on Friday. They issued a “sell” rating on the stock.

Sangamo Therapeutics Trading Up 9.9 %

SGMO opened at $0.44 on Friday. Sangamo Therapeutics has a 1-year low of $0.29 and a 1-year high of $1.67. The firm has a 50-day moving average price of $0.50 and a two-hundred day moving average price of $0.61. The stock has a market capitalization of $90.97 million, a PE ratio of -0.24 and a beta of 1.24.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.05). The firm had revenue of $0.48 million during the quarter, compared to the consensus estimate of $8.51 million. Sangamo Therapeutics had a negative net margin of 1,749.06% and a negative return on equity of 182.55%. During the same quarter in the prior year, the business earned $0.12 EPS. On average, research analysts predict that Sangamo Therapeutics will post -0.55 EPS for the current year.

Hedge Funds Weigh In On Sangamo Therapeutics

A number of institutional investors have recently added to or reduced their stakes in SGMO. Wasatch Advisors LP lifted its holdings in Sangamo Therapeutics by 62.4% during the 1st quarter. Wasatch Advisors LP now owns 20,132,324 shares of the biopharmaceutical company’s stock worth $13,493,000 after purchasing an additional 7,734,400 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in Sangamo Therapeutics in the first quarter valued at about $331,000. Acadian Asset Management LLC lifted its position in Sangamo Therapeutics by 4.0% during the first quarter. Acadian Asset Management LLC now owns 4,943,260 shares of the biopharmaceutical company’s stock worth $3,311,000 after purchasing an additional 192,385 shares during the period. Assenagon Asset Management S.A. lifted its holdings in shares of Sangamo Therapeutics by 14.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 1,033,322 shares of the biopharmaceutical company’s stock worth $561,000 after acquiring an additional 129,811 shares during the period. Finally, SG Americas Securities LLC boosted its position in shares of Sangamo Therapeutics by 103.9% during the 4th quarter. SG Americas Securities LLC now owns 180,544 shares of the biopharmaceutical company’s stock worth $98,000 after acquiring an additional 92,002 shares in the last quarter. 56.93% of the stock is currently owned by institutional investors and hedge funds.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.